checkAd

Seagen to Host Conference Call and Webcast Discussion on September 21, 2021 to Discuss TIVDAK (tisotumab vedotin-tftv) Approval

Nachrichtenquelle: Business Wire (engl.)
20.09.2021, 23:05  |  101   |   |   

Seagen Inc. (Nasdaq: SGEN) will host a conference call and webcast on Tuesday, September 21, 2021 to discuss the U.S. Food and Drug Administration approval of TIVDAK (tisotumab vedotin-tftv). Access to the event can be obtained as follows:

September 21, 2021

6:00 a.m. Pacific Time / 9:00 a.m. Eastern Time

  • Telephone 844-763-8274 (U.S.) or +1 412-717-9224 (international); conference ID 10160278
  • Webcast with slides will be available at www.seagen.com in the Investors section. A webcast replay will be archived on the Company’s website.

About Seagen

Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on the company’s marketed products and robust pipeline, visit www.seagen.com and follow @SeagenGlobal on Twitter.

Seagen Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de



Wertpapier



0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Seagen to Host Conference Call and Webcast Discussion on September 21, 2021 to Discuss TIVDAK (tisotumab vedotin-tftv) Approval Seagen Inc. (Nasdaq: SGEN) will host a conference call and webcast on Tuesday, September 21, 2021 to discuss the U.S. Food and Drug Administration approval of TIVDAK (tisotumab vedotin-tftv). Access to the event can be obtained as follows: September …

Community

Nachrichten des Autors

Titel
Titel
Titel
Titel

Nachrichten zu den Werten

DatumTitel
12.10.21Seagen and Astellas Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV (enfortumab vedotin-ejfv) With Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer
Business Wire (engl.) | Weitere Nachrichten
07.10.21Seagen to Host Conference Call and Webcast Discussion of Third Quarter 2021 Financial Results on October 28, 2021
Business Wire (engl.) | Weitere Nachrichten
28.09.21Seagen Announces Last Patient Enrolled in Phase 2 MOUNTAINEER Trial Evaluating TUKYSA (Tucatinib) Regimen in HER2-Positive Metastatic Colorectal Cancer
Business Wire (engl.) | Weitere Nachrichten
27.09.21Japan’s MHLW Approves PADCEV (enfortumab vedotin) for Advanced Urothelial Cancer
Business Wire (engl.) | Weitere Nachrichten
25.09.21Chartgalerie - Top / Flop Aktien Wochenrückblick Kalenderwoche 38/21
w:o Chartvergleich | Chartanalysen
20.09.21Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
Business Wire (engl.) | Weitere Nachrichten
20.09.21Seagen and Genmab Announce FDA Accelerated Approval for TIVDAK (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
Business Wire (engl.) | Weitere Nachrichten
19.09.21Seagen and Genmab Present Interim Results From the innovaTV 205 Study for Tisotumab Vedotin Combination Therapy Treatment of Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2021
Business Wire (engl.) | Weitere Nachrichten